Vertical Research upgraded Amrize (AMRZ) to Buy from Hold with an unchanged price target of $70.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize reports Q1 EPS (16c), consensus (14c)
- Amrize reaffirms FY26 revenue view $12.29B-$12.52B, consensus $12.42B
- Amrize lifts Q1 revenue, boosts shareholder returns and reaffirms 2026 outlook
- Amrize shareholders approve all proposals at General Meeting
- Amrize Shareholders Approve Dividends and Board Changes at First AGM